Analysis of RNA metabolism in peripheral WBCs of TDP-43 KI mice identifies novel biomarkers of ALS  by Hasegawa, Minami et al.
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Diagnostic  biomarkers  for amyotrophic  lateral  sclerosis  (ALS)  have  yet  to  be identiﬁed.  One  of  the  causes
of neuronal  cell  death  in  neurodegenerative  diseases  is  abnormal  RNA  metabolism,  although  the mech-
anisms  by  which  this  occurs  are  unclear.  Detection  of abnormal  RNA metabolism  in white  blood  cells
(WBCs)  could  lead  to a new  biomarker  of ALS  onset.  TAR  DNA-binding  protein  43 kDa  (TDP-43) is an
RNA-binding  protein  that regulates  RNA  metabolism.  We  previously  developed  a mouse  model  of  ALS
that  exhibits  adult-onset  motor  dysfunction;  these  mutant  TDP-43  knock  in  (KI)  mice  heterozygously
express  mutant  human  TDP-43  (A382T  or G348C).  In the  present  study,  we examined  TDP-43  mRNA
levels  in WBCs  of  KI mice  and found  that  A382T  mutant  mRNA  is  signiﬁcantly  higher  than  G348C.  Ouriomarker
DP-43
NA metabolism
eripheral blood cells
results  suggest  that each  mutant  TDP-43  induces  distinct  RNA  metabolism,  and  that  the  expression  of
total  TDP-43  alone  in  WBC  is  not  suitable  as an ALS  biomarker.  To  identify  additional  candidates,  we
focused  on  survival  and  apoptosis-related  factors  and  examined  their  mRNA  metabolism  in WBCs.  mRNA
levels of both  Smn1  and  Naip5  correlated  with  TDP-43  levels  and also differed  between  A382T and  G348C.
Together,  TDP-43  and  these  factors  may  enable  detection  of  abnormalities  in  individual  ALS  pathologies.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ase that selectively affects motor neurons (MNs) and leads to a
rogressive loss of motor function, paralysis, and death. In most
ases, ALS is an adult-onset disease, and patients develop respira-
ory failure within 3–5 years of diagnosis (Rowland and Shneider,
001). There are no effective cures for ALS, but riluzole has been
hown to delay progression and prolong survival by an average of
 months (Rowland et al., 2001). Although the majority of ALS cases
re sporadic (sALS), approximately 10% are familial (fALS) (Rowland
nd Shneider, 2001). In familial cases, gene mutations have been
dentiﬁed at many ALS-associated gene loci (Kwiatkowski et al.,
∗ Corresponding author at: 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 1058461,
apan. Tel.: +81 3 3433 1111/3 5400 1200x2350; fax: +81 3 5400 1297.
∗∗ Corresponding author at: 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582,
apan. Tel.: +81 3 5363 3747; fax: +81 3 3357 5445.
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H.J. Okano).
ttp://dx.doi.org/10.1016/j.neures.2015.11.009
168-0102/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2009; Deng et al., 2011; Renton et al., 2011; Wu et al., 2012). For
example, more than 20 years ago, the Cu/Zn superoxide dismutase
1 (SOD1) gene was identiﬁed as being responsible for familial ALS
for the ﬁrst time (Rosen et al., 1993).
In ALS, the accumulation of abnormal proteins in affected MNs
is a neuropathological hallmark. The TARDNA binding protein 43
(TDP-43) is a major component of ubiquitin-positive neuronal
inclusions in both ALS and frontotemporal dementia. Normally,
TDP-43 localizes in cell nuclei; however, in ALS MNs  it is found
in the cytoplasm (Arai et al., 2006; Neumann et al., 2006). The
pathological mutations responsible for ALS are mainly found in
the TDP-43 C-terminal domain, which contains highly conserved
glycine-rich regions (Gitcho et al., 2008; Kabashi et al., 2008;
Sreedharan et al., 2008; Yokoseki et al., 2008). Mutations in TDP-43
account for approximately 4% of fALS and a smaller percentage of
sALS (Chiò et al., 2012).
Recently, it has been proposed that RNA metabolism is related to
MN degeneration. In fact, half of the genes responsible for fALS have
been found to be associated with RNA metabolism (Droppelmann
et al., 2014). TDP-43 is an RNA-binding protein that regulates
metabolism of target RNA, pre-mRNA splicing, mRNA stability, and
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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ransport (Buratti et al., 2001). Previously, we  used two  TDP-43
utations, A382T and G348C, to produce mutant TDP-43 knock-
n (KI) mice as an ALS model. These mice show poor weight gain
nd gradually exhibit adult-onset motor dysfunction from seven
onths of age, making them a useful model for pathological anal-
sis of symptom progression.
There are no biomarkers of MN degeneration, and thus diag-
osis of ALS still depends on clinical symptoms (Valadi, 2015).
onsequently, there is a pronounced delay between symptom
nset and diagnosis. Furthermore, long delays in diagnosis mean
hat treatment for the progressing disease often occurs too late
o be optimally effective. Various techniques have been proposed
o identify biomarkers, including diagnostic magnetic resonance
maging of the brain or spinal cord, although it is difﬁcult to identify
atients at risk in the non-symptomatic stage of ALS (Pradat and El
endili, 2014). Another method consists of performing proteasome
nalysis of the cerebrospinal ﬂuid (CSF) of ALS patients (Tarasiuk
t al., 2012); however, this approach is invasive and can be painful.
hus, in the present study, we searched for ALS biomarkers using
eripheral blood cells of mutant TDP-43 KI mice. We hypothesize
hat abnormal RNA metabolism related to TDP-43 mutants may
erve as a useful biomarker for the assessment of ALS progression.
e investigate the expression and mRNA levels of TDP-43, as well
s shifts in mRNA levels of survival and apoptosis-related factors in
hite blood cells (WBCs) of KI mice.
. Experimental procedures
.1. Animals
Experimental procedures and housing conditions for animals
ere approved by the Jikei University Animal Ethics Committees
approval number, 24-019). The mutant TDP-43 KI mice had human
DP-43, including C-terminal point mutations of amino acids fused
ith Venus, Ala to Thr in 382 (A382T) or Gly to Cys in 348 (G348C).
etails on the genetic development and behavioral and patholog-
cal analysis of these two KI mice will be described in a separate
eport, now in preparation.
.2. Peripheral blood and organ collection
The mice were anesthetized using isoﬂurane (Pﬁzer, New York,
Y, USA), and peripheral blood cells were collected from their
earts using a 26-G needle and 1 mL  heparinized syringe. Blood
amples were treated for each experiment. The heart, lung, liver,
pinal cord, and brain were collected, and RNA isolations were
mmediately performed.
.3. siRNAs
siDirect 2.0 software was used to design novel siRNAs (Fig. S1).
hree siRNAs were designed for the 3′-UTR sequence of mouse TDP-
3. There is no 3′-UTR sequence in mutant human TDP-43::Venus,
nd the KI gene was not silenced by siRNAs for mouse TDP-43.
e selected a siRNA exhibiting a high silencing effect from these
hree candidates (Fig. S2). KI gene silencing was  targeted to Venus
equences (Fig. S1). Total TDP-43 gene silencing was performed
sing mixtures of each volume of mouse TDP-43 siRNA and Venus
iRNA. The siRNA sequences were described in supplementary
ethod.
.4. AntibodiesThe following antibodies were used for western blotting: Anti-
DP-43 (Proteintech, Chicago, IL, USA), 1:1000; anti-GFP (MBL,
agoya, Japan), 1:1000; -actin (Sigma, St. Louis, MO,  USA), 1:2000;Research 106 (2016) 12–22 13
horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Mil-
lipore, Darmstadt, Germany), and goat anti-mouse (Millipore),
1:2000. For immunocytochemistry, anti-TDP-43, anti-GFP, goat
anti-mouse Alexa 633 (Molecular Probes, Eugene, OR,  USA), and
goat anti-rabbit Alexa 647 (Molecular Probes) were used at 1:100.
Hoechst33342 (Molecular Probes) was  used at 1:100,000,000.
2.5. Cell culture and transfection
Astrocytes were isolated from the brain cortices of P1
mutant TDP-43 KI mice. The cells were maintained in high-
glucose DMEM (SIGMA) with 20% heat-inactivated fetal bovine
serum (Thermo Scientiﬁc, Waltham, MA,  USA) and 100 g/mL
penicillin–streptomycin solution (Wako, Osaka, Japan). siRNAs
were transfected into cells using Lipofectamine®RNAi MAX
Reagent (Invitrogen, Carlsbad, CA, USA). After 48 h in culture, the
cells were collected and used in a protein isolation step.
2.6. RNA isolations and real-time RT-PCR
Total RNA was  extracted from each organ of the mice using
TRIzol® reagent (Invitrogen) and RNeasy® Plus Mini Kit (Qiagen,
Hilden, Germany). For real-time RT-PCR, ﬁrst-strand cDNA synthe-
sis was  performed using the PrimeScript® RT Master Mix  (Takara
Bio, Shiga, Japan) following the manufacturer’s protocol. Real-time
RT-PCR was  performed using a TaqMan® Gene Expression Assay
Master Mix  (Applied Biosystems, Foster City, CA, USA) with an ABI
7300 Real-time PCR system (Applied Biosystems). The mRNA lev-
els in the samples were normalized using beta-actin. For RT-PCR,
ﬁrst-strand cDNAs were synthesized using ReverTra Ace  (TOY-
OBO, Osaka, Japan), according to the manufacturer’s protocol. PCR
ampliﬁcation was performed using KOD plus enzyme. TaqMan®
MGB  probes, primers and ampliﬁcation conditions were described
in supplementary method.
2.7. Protein extraction
Protein extraction from cultured astrocytes was performed
using mixture of Complete Mini (Roche Basel, Switzerland) and
Tissue Extraction Reagent I (Invitrogen) containing 50 mM Tris (pH
7.4), 250 mM NaCl, 5 mM EDTA, 2 mM Na3VO4, 1 mM NaF, 20 mM
Na4P2O7, and 0.02% NaN3 was added into each culture well. After
intense dissociation, the extracts were incubated for 5 min  on ice.
Centrifugation was  performed at 20,000 × g for 15 min, and the
lysates were stored at −80 ◦C.
2.8. Western blotting
Samples were diluted with equal volumes of Laemmli Sample
Buffer (Bio Rad, Hercules, CA, USA) containing 62.5 mM Tris-HCl
(pH 6.8), 25% glycerol, 2% SDS, 0.01% Bromophenol Blue, and
5% 2-mercaptoethanol, then incubated for 3 min at 95 ◦C. Pro-
tein samples were separated using SDS-PAGE and transferred to
polyvinylidene diﬂuoride membranes (Millipore). The membranes
were blocked with 1% non-fat skim milk for 30 min  at room
temperature (RT) and incubated in primary antibody solutions
for 16 h at 4 ◦C. Thereafter, the membranes were incubated with
secondary antibodies for 2 h at RT. Signals were detected using
Chemiluminescence HRP Substrate (Takara Bio) with a LAS3000
Mini (FUJI FILM, Tokyo, Japan). Semi-quantitative analysis of the
signals was performed using ImageJ software (National Institute of
Health).
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Fig. 1. Mutant TDP-43 is expressed in various tissues of mutant TDP-43 KI mice. (A)
Schematic representation of the domain architecture of the transgene. Filled boxes
and  lines represent exons (Ex) or introns of the Tardbp genome, respectively. The
mice express human mutant TDP-43::Venus, which has TDP-43 point mutations
in  amino acids A382T and G348C. The transgene cut into exon2 of mouse Tardbp.
Met, methionine residue; Stp, stop codon. (B) mRNA expression of the transgene in4 M. Hasegawa et al. / Neurosc
.9. Immunocytochemistry
Whole blood cells were ﬁxed in 4% paraformaldehyde solution
or 3 min  at RTHemolyzed red blood cells were removed by PBS
ash, and the cells were incubated in 5% bovine serum albumin/PBS
olution for 1 h at RT. Primary antibody was dissolved in block-
ng solution, and the cells were incubated for 1 h at RT, and then,
ncubated in secondary antibody solution 1 h at RT. The cells were
issociated in PBS containing 0.05% NaN3 and enclosed under a cov-
rslip. Microscopy was performed using a ﬂuorescence microscope
IX73; Olympus, Tokyo, Japan) equipped with an objective lens
UPlanSApo 60× N.A. = 1.35; Olympus), a 0.5× zoom lens (Olympus)
nd a charge-coupled device camera (Cool SNAP EZ; Photomet-
ics, Tucson, AZ, USA). The microscope was driven by MetaView
oftware. The photographic conditions were described in supple-
entary method.
.10. Fluorescence microscopy condition and image analysis
Lymphocytes which selected by cell size less than 30 m2 were
maged by ﬂuorescent microscopy (Olympus, IX73). The devia-
ion was calculated by measuring pixel intensity of each cell. High
eviation produced and kept the localization of TDP-43 as high non-
niformity. Details of photographic conditions were described in
upplementary methods.
.11. Statistical analysis
Statistical signiﬁcance was determined using the unpaired t-test
s detailed in the ﬁgure legends.
. Results
.1. Mutant TDP-43 mRNA was ubiquitously expressed in mutant
DP-43 KI mice
In our experiment, we use mutant TDP-43 KI mice exhib-
ted late-onset motor dysfunction and poor weight gain, although
anuscript about development of this mice is in preparation. These
ice had mutant human TDP-43 (A382T or G348C) fused with
enus, and the transgene cut into exon 2 of the mouse Tardbp
enome (Fig. 1A). In these KI mice, the transgene was expressed
eterozygously due to the dominant heredity of the mutant TDP-
3 gene. In addition, it was  possible to detect wild type (WT) mouse
DP-43 and the KI gene separately by targeting Venus as a reporter.
e performed RT-PCR analysis in multiple organs, including heart,
ung, liver, spinal cord, brain, and WBCs in TDP-43 (A382T) KI mice
t the symptomatic stage. Mutant TDP-43 mRNA was  ubiquitously
xpressed in each tissue (Fig. 1B). We  also analyzed mRNA expres-
ion patterns of WT  mouse TDP-43 and found that they also were
biquitously expressed (data not shown).
.2. The ratio of mutant TDP-43 increased in glial cells of A382T
utant mice relative to that in G348C mutants
We  ﬁrst investigated expression patterns of TDP-43 in the
entral nervous system (CNS) using primary cultured astrocytes
ollected from TDP-43 KI mice. Western blotting was carried out to
eparately detect expression of mouse and mutant human TDP-
3. Anti-TDP-43 antibody detected WT  mouse TDP-43 (43 kDa)
nd mutant human TDP-43::Venus (70 kDa; Fig. 2A and C). Pro-
ein expression derived from the transgene was also detected by
nti-GFP antibody (70 kDa; Fig. 2A and D). WT  mouse TDP-43
xpression level was decreased by half in A382T cells relative to that
n WT  astrocytes (Fig. 2C). The change in mutant TDP-43 expres-
ion level detected by the anti-GFP antibody was not signiﬁcant, butvarious organs of TDP-43 (A382T) KI mice aged 10 months. Transgene detections
were performed by designing primers that bound Venus sequences. Mutant TDP-43
was ubiquitously expressed in the mice. NTC, non-template control.
tended to increase in A382T astrocytes, which corresponded to the
results from anti-TDP-43 antibody detection (Fig. 2D). In astrocytes
carrying each mutation, no signiﬁcant difference in total TDP-43
expression levels were observed (Fig. 2B), but the ratio of mutant
TDP-43 expression was  two-fold higher in A382T astrocytes rela-
tive to those in G348C astrocytes (Fig. 2E). Our data thus suggest
that in the CNS of KI mice, the metabolism of TDP-43 in mutant
A382T and G348C differs.
3.3. Mutant TDP-43 can be also involved in negative feedback
loop of autoregulation
To elucidate the regulation mechanisms of mouse and mutant
human TDP-43 expression in KI mice, knock-down (KD) experi-
ments were performed in KI astrocytes using siRNAs (Fig. 3). We
demonstrated individual silencing in mouse and (or) mutant TDP-
43 and analyzed the responsivity of expression in each. The siRNA
designs are described in Fig. S1. Mutant human TDP-43 KD was
performed by targeting sequences of Venus. For WT  mouse TDP-43
KD, we designed three siRNAs that bound to 3′UTR and selected
siRNA 3 (Fig. S2). A mouse and mutant humanTDP-43 siRNA mix-
ture was used for total TDP-43 KD. In the two  mutant astrocytes, an
approximate 1.5-fold increment of WT mouse TDP-43 was  induced
by mutant human TDP-43 silencing. Conversely, mutant human
TDP-43 expression levels were not affected by WT  mouse TDP-43
KD (Fig. 3A, C, E and G). Moreover, the total TDP-43 expression
levels were complemented by WT mouse TDP-43 upregulation
induced by mutant human TDP-43 KD (Fig. 3B and F). Expression
and localization patterns of mutant human TDP-43, detected by
the anti-TDP-43 antibody corresponded to those from the anti-GFP
antibody (Fig. 3D and H). We  did not detect a signiﬁcant differ-
ence in self-regulation between A382T and G348C. At least, WT
TDP-43 encoding mRNA, but not human mutant TDP-43 encod-
ing mRNA, is regulated by both WT  and mutant TDP-43 through
the 3′UTR.
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Fig. 2. Expression of TDP-43 is different between two types of mutant TDP-43 KI mice in cultured astrocytes. (A) Western blotting of TDP-43 expression in primary cultured
astrocytes from mutant TDP-43 KI mice. Anti-TDP-43 antibodies were used to detect WT mouse TDP-43 (43 kDa) and mutant TDP-43::Venus (70 kDa). Venus fused TDP-43
protein was  also detected by an antibody against GFP (70 kDa). (B–E) Quantitative analysis of each band detected by anti-TDP-43 (B, C) and anti-GFP antibodies (D). In (B), the
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 = 3 of each genotype. Quantitative analysis was performed using ImageJ software
.4. Mutant and normal TDP-43 were detected individually in
BCs of mutant TDP-43 KI mice
To investigate whether the differences between A382T and
348C also occurred in WBCs of KI mice, we attempted to individ-
ally detect expression of mutant and WT  mouse TDP-43 by WBCs
mmunocytochemistry. These TDP-43 KI mice showed motor dys-
unction at seven months (Hara-Miyauchi et al., in preparation),
nd so we performed experiments using mice aged four months,
hich we considered to be a presymptomatic stage. Mutant human
DP-43 expression was detected by anti-GFP antibody or ﬂuores-
ence of Venus, and the signals were predominantly merged in the
ucleus (Fig. 4A). Localization of mutant human and WT  mouse
DP-43 were detected by anti-TDP-43 antibody (Fig. 4B). In the
T mice WBCs, Venus ﬂuorescence was not observed, but TDP-43
xpression was detected by anti-TDP-43 antibody (Fig. 4B). Cor-
esponding to mutant TDP-43 protein, the signals detected by the
ntibody were mainly observed in the nucleus.
.5. Expression of TDP-43 also changed in WBCs between the two
utant mice
We  focused on TDP-43 expression in WBCs and performed ﬂu-
rescence intensity analysis. Using ImageJ software, we selected
ymphocytes by cell size and nucleus morphology (Fig. S3A and B).
efore selection, the standard deviation (SD) of the cell size
ncreased, and after the selection, the dispersion was minimized
Fig. S3A and B). Thereafter, we analyzed the ﬂuorescence inten-
ity of total or mutant TDP-43 signals in WBCs at the age of
our (presymptomatic) and seven (symptomatic stage) months
Fig. 5). Total TDP-43 signals detected by the anti-TDP-43 anti-
ody increased more than two-fold in A382T relative to those inTDP-43. In (C), WT mouse TDP-43 (43 kDa) was decreased in A382T relative to that
and WT mouse TDP-43 [G348C, 0.522 (SD = 0.046) relative to A382T (p = 0.00009)].
were analyzed using an unpaired t-test (*p < 0.05, **p < 0.01).
WT  and G348C at four months of age (Fig. 5A). At seven months,
the signals also tended to increase, although the number of statis-
tically signiﬁcant differences decreased (Fig. 5A). The ﬂuorescence
intensities of mutant TDP-43::Venus increased 1.8-fold in A382T
mutant mice in the presymptomatic stage and symptomatic stage
(Fig. 5B). And in G348C, signiﬁcant increase was observed in symp-
tomatic stage than presymptomatic stage (Fig. 5A and B). In contrast
to G348C, signiﬁcant decrease between the stages was detected in
total TDP-43 of A382T mice (Fig. 5A). Furthermore, we scored corre-
lations between expression and non-uniformity of TDP-43 signals
(Fig. 5C–F). We  deﬁned deviation in the ﬂuorescence intensity of
each cell as non-uniformity. In the presymptomatic stage, the ﬂuo-
rescence intensity and non-uniformity of total and mutant TDP-43
tended to increase in A382T (Fig. 5C and E). In the symptomatic
stage, the total TDP-43 signals and dispersion also increased in
A382T, which corresponded to the mutant TDP-43 signals (Fig. 5D
and F). The results from staining intensity were consistent with the
ﬂuorescence intensity results, suggesting that stainability did not
inﬂuence the expression analysis. Collectively, our results indicate
that expression changes in TDP-43 occurred in WBCs of KI mice and
that the degree of change varied between TDP-43 with different
mutational positions.
3.6. mRNA metabolism of TDP-43 was  altered in WBCs of mutant
TDP-43 KI mice
It has recently been suggested that RNA metabolism, includ-
ing RNA splicing, stability, and degradation, may  be related to
MN degeneration. Therefore, we  hypothesized that abnormal RNA
metabolism related to TDP-43 occurred in WBCs. To assess TDP-
43 mRNA expression in mutant TDP-43 KI mice, real-time RT-PCR
analysis was performed using TaqMan® MGB  probes (Fig. 6). The
16 M. Hasegawa et al. / Neuroscience Research 106 (2016) 12–22
Fig. 3. Total TDP-43 expression level is regulated only by WT mouse TDP-43 in cultured astrocytes of the KI mice. (A, E) Western blotting of cultured astrocytes showed that
TDP-43  expression was  silenced by siRNA. (B–D, F–H) Quantitative analysis of expression levels were detected by different antibodies. (A–D) A382T and (E–H) G348C. Mouse
TDP-43  siRNA was  designed in the 3′-UTR in mouse TDP-43 mRNA, which led to KD of WT mouse TDP-43 only and not mutant human TDP-43. Mutant TDP-43::Venus was
silenced by targeting mRNA of Venus. Total TDP-43 KD was performed using a mixture of mouse TDP-43 and Venus siRNA. KD experiments were performed three times
for  each genotype. In (C) and (G), increases in WT mouse TDP-43 expression levels were induced by mutant TDP-43 KD. A382T, 1.47 (SD = 0.25), p > 0.05; and G348C, 1.53
(SD  = 0.18), p = 0.03 relative to control. Data were analyzed using an unpaired t-test (*p < 0.05).
M. Hasegawa et al. / Neuroscience Research 106 (2016) 12–22 17
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pig. 4. Individual visualization of mutant and normal TDP-43 localization in WBCs of
BCs  at 4 months of age. Mutant TDP-43 expression was detected by ﬂuorescence
nti-TDP-43 antibody. BF, Bright ﬁeld, Scale bar, 5 M.
aqMan® designs are described in Supplementary Fig. 4. Total TDP-
3 mRNA was detected by targeting the homologous domains of
ouse TDP-43 and transgene allele. Notably, the mRNA expression
evel of total TDP-43 was signiﬁcantly decreased in G348C mutant
ice WBCs relative to those in A382T and WT  (Fig. 6A). In addi-
ion, the mRNA expression patterns of mutant TDP-43 were also
ifferent between the A382T and G348C mutant mice (Fig. 6B). We
lso examined mRNA levels of total, mutant and mouse TDP-43 in
rain cortex of the KI mice and the result indicated that mRNA level
f mouse TDP-43 was signiﬁcantly lower in A382T than G348C KI
ice (Fig. S5). Overall, these data suggest that mRNA metabolism
iffers in KI mice carrying A382T or G348C mutations of TDP-43.
.7. mRNA metabolism of MN  survival and anti-apoptotic factors
hanged in WBCs of mutant TDP-43 KI mice
Our data suggest that RNA metabolism varies in different types
f mutant TDP-43 KI mice. Thus, in ALS, RNA metabolism may
e individually distinct. To study this, we used a combination of
eurodegeneration-related factors, including TDP-43. Using sur-
ival motor neuron1 (Smn1) and neuronal apoptosis inhibitory
rotein (Naip), we performed mRNA expression analysis. The
RNA expression pattern of Smn1 was similar to that of total TDP-
3 (Fig. 6C). In the mouse, seven genes that are highly homologous
ith Naip have been found, and four of them, including Naip1, 2,
, and 6, have been reported to have transcripts (Diez et al., 2003).
e  used RT-PCR and sequence analysis to show that Naip5 was
redominantly expressed in WBCs of KI mice (data not shown).nt TDP-43 KI mice. (A, B) Immunocytochemical analysis of mutant TDP-43 KI mouse
nus (A, B) and anti-GFP antibody (A). (B) Total TDP-43 expression was detected by
The mRNA expression pattern of Naip5 showed an inverse correla-
tion with that of total TDP-43 and Smn1 (Fig. 6D). In addition, we
analyzed the mRNA expression level of a Naip5 splice variant. By
performing RT-PCR and sequence analysis, we identiﬁed the exon
11 skipping splice variant of Naip5 in the KI mice WBCs. Although
no reports have described a role of splice variants, we hypothe-
sized that accumulation of abnormal splice variants occurred in KI
mice WBCs. The mRNA expression pattern of an exon skipping vari-
ant of Naip5 was  similar to that of total Naip5, in other words, we
failed to detect abnormal splice variants of Naip5 (Fig. 6E). How-
ever, this concept may  apply to unknown factors that are related to
aberrant RNA metabolism. These results show that a combination
of MN degeneration-related factors may  enable determination of
RNA metabolism in individual ALS patients.
4. Discussion
In the present study, TDP-43 RNA metabolism in the CNS
and peripheral blood varied between two different types of
mutant TDP-43 mice, and MN degeneration-related factors
appeared to correlate with these differences. Detection of RNA
metabolism in peripheral blood may  thus reﬂect abnormalities
in the CNS. Regarding TDP-43 metabolism, protein aggregation
mechanisms have been discussed extensively in previous reports
(Arai et al., 2006; Neumann et al., 2006; Kabashi et al., 2008;
Swarup et al., 2011; Xiao et al., 2015). However, few studies
have compared mutant TDP-43 function at the whole-body level.
18 M. Hasegawa et al. / Neuroscience Research 106 (2016) 12–22
Fig. 5. Fluorescence intensity analysis of WBC  images from mutant TDP-43 KI mice. (A, B) Fluorescence intensity quantiﬁcation of total TDP-43 (A) or mutant TDP-43::Venus
(B)  in WBCs of the mice at the age of 4 and 7 months. (A) At 4 months: WT,  465.59 (SD = 90.48); A382T, 1390.40 (SD = 464.02); G348C, 284.27 (SD = 52.39); p = 0.000004
(A382T) and p = 0.00002 (G348C) compared with WT,  and p = 0.0000006 for the comparison between A382T and G348C. At 7 months: WT,  515.02 (SD = 235.11); A382, 707.16
(SD  = 248.18); G348C, 478.94 (SD = 212.93); p = 0.015 (A382T) and p > 0.05 (G348C) compared with WT,  and p = 0.020 for the comparison between A382T and G348C. N = 15,
14,  and 9 at 4 months; n = 27, 16, and 11 at 7 months for each genotype. (B) At 4 months: A382T, 578.41 (SD = 156.19); G348C; 321.14 (SD = 64.02); p = 0.00001. At 7 months:
A382T, 575.89 (SD = 140.81); G348C; 462.45 (SD = 116.44); p = 0.03. N = 15 and 14 at 4 months; n = 15 and 15 at 7 months for each genotype. Data were analyzed using an
u ensity
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gnpaired t-test (*p < 0.05, ***p < 0.001). (C–F) Correlation between ﬂuorescence int
enus  signals (E, F) in cells of mice at age 4 (C, E) and 7 (D, F) months. Deviation of ﬂu
he  analysis of ﬂuorescence intensity was performed using ImageJ software. N = 15
ost investigations using animal models have been conducted
n transgenic animals, and as such, TDP-43 was designed to be
verexpressed using optional promoters and thus does not reﬂect
hysiological conditions. In our study, mice with mutant human
DP-43 knocked in were used. Similar to ALS patients, in heterozy-
ous human TDP-43 KI mice, the transgene was expressed using
he endogenous TDP-43 promoter. Therefore, for the ﬁrst time,
hese experimental conditions enabled the physiological exam-
nation of TDP-43 expression. Furthermore, the Venus reporter
ene was fused to TDP-43, allowing individual expression analysis and deviation of total TDP-43 signals detected by anti-TDP-43 antibody (C, D) or
nce intensity was considered to be a non-uniformity of mutant TDP-43 localization.
nd 9 at 4 months; n = 13, 16, and 11 at 7 months of each genotype.
of normal and mutant TDP-43. Using these mice, we show the
ratio of TDP-43 (with either the A382T or G348C mutation) levels
in the CNS. In previous studies, the two  mutant human TDP-43
proteins were found to have long half-lives, and patients with
these mutations tended to have juvenile-onset disease (Kabashi
et al., 2008; Corrado et al., 2009; Watanabe et al., 2013). Regarding
differences between mutants, a decrease in G348C mutant protein
expression in cultured MNs  has been reported (Kabashi et al.,
2010). Consistent with these ﬁndings, we observed that mutant
human TDP-43 was expressed at higher levels in A382T than in
M. Hasegawa et al. / Neuroscience Research 106 (2016) 12–22 19
Fig. 6. Changes in RNA metabolism in the WBCs of mutant TDP-43 KI mice. (A–E) Real-time RT-PCR analysis of mutant TDP-43 KI mice WBCs at 4–22 months of age. mRNA
expression levels detected by TaqMan® MGB  probes binding total TDP-43 (A) and mutant TDP-43 (B). (A) Total TDP-43 mRNA expression was  decreased in G348C at 4–22
month  old mice relative to those in WT and A382T. Relative to WT:  G348C, 0.34 (SD = 0.11), p = 0.004 (4 months); 0.33 (SD = 0.10), p = 0.009 (7 months), 0.23 (SD = 0.13),
p  > 0.05 (22 months). Relative to A382T: p = 0.00003 (4 months), p = 0.013 (7 months), p = 0.002 (22 months). A382T relative to WT:1.31 (SD = 0.33; 4 months); 0.92 (SD = 0.51;
7  months); 0.51 (SD = 0.17; 22 months). Total TDP-43 probe was  targeted to common sequences of mouse and mutant human TDP-43. (B) Mutant TDP-43 mRNA expression
was  decreased in G348C relative to that of A382T. G348C, 0.45 (SD = 0.10), p = 0.0000007 (4 months); 0.41 (SD = 0.08), p = 0.002 (7 months); 0.39 (SD = 0.24), p > 0.05. Transgene
mRNA was detected by probes designed for Venus sequences. (C–E) mRNA expression of Smn1 (C) and Naip5 (D, E), known to be related to MN survival and anti-apoptotis.
In  Smn1, relative to WT:  G348C, 0.37 (SD = 0.18), p = 0.002 (4 months); 0.34 (SD = 0.09), p = 0.048 (7 months); 0.36 (SD = 0.16), p = 0.034 (22 months). Relative to A382T:
p  = 0.0000003 (4 months); p = 0.00005 (7 months), p = 0.000006 (22 months). A382T relative to WT:  1.57 (SD = 0.29), p = 0.018 (4 months); 1.16 (SD = 0.29), p > 0.05 (7 months);
0.93  (SD = 0.17) p > 0.05 (22 months). (D) Total Naip5 detected by a probe set into non-exon skipping sequences. Relative to WT:  G348C, 2.27 (SD = 1.43), p = 0.027 (4 months);
2.71  (SD = 0.96), p = 0.0005 (7 months); 1.91 (SD = 0.75), p = 0.05 (22 months). Relative to A382T: p = 0.013 (4 months), p = 0.00015 (7 months), p = 0.00037 (22 months).
A382T  relative to WT:  0.41 (SD = 0.14), p = 0.046 (4 months), 0.35 (SD = 0.26), p = 0.0094 (7 months); 0.23 (SD = 0.093), p = 0.012 (22 months). (E) Naip5 splice variant (sv) was
performed by targeting the exon10 and 12 junction. Relative to WT:  G348C, 2.30 (SD = 1.57), p = 0.032 (4 months); 2.84 (SD = 1.24), p = 0.0009 (7 months); 1.76 (SD = 0.69),
p ths), 
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r = 0.031 (22 months). Relative to A382T: p = 0.018 (4 months), p = 0.00052 (7 mon
onths); 0.25 (SD = 0.22), p = 0.0071, (7 months); 0.15 (SD = 0.051), p = 0.045 (22 mo
2  months). Data were analyzed using an unpaired t-test (*p < 0.05, **p < 0.01, ***p <
348C astrocytes (Fig. 2E). Recently, non-cell autonomous signal
rom glial cells were thought to be related with neurodegeneration
n ALS. For example, overexpression of ALS associated mutant
DP-43 driven by an astrocytic promoter was sufﬁcient to cause
otor neuron degeneration in rats and was also associated with
ctivation of astrocytes (Tong et al., 2013). Thus, we  selected
strocytes in CNS analysis because the cells may  play a key role
n TDP-43 pathology. And then, we also examined mRNA levels
f total, mutant and mouse TDP-43 in brain cortex of the KI mice
Fig. S5). The mRNA levels were not corresponding to protein level
ompletely, but higher in A382T than G348C (Fig. 2 and Fig. S5). It
s surprising that protein functions can differ so signiﬁcantly as a
esult of substitution of only two amino acids.and p = 0.00029 (22 months). A 382 T relative to WT:  0.39 (SD = 0.15) p = 0.043 (4
 N = 13, 15, and 16 in WT;  N = 8, 8, and 8 in A382T; N = 7, 8, and 8 in G348C (4, 7, and
).
To further understand these differences, we investigated the
regulation of the two TDP-43 mutants in KI mice astrocytes. In KD
experiments, the reduction of mutant human TDP-43 induced an
increase in normal TDP-43, and total TDP-43 level was constantly
regulated. In contrast, when the total expression level was  reduced
with WT  mouse TDP-43 siRNA, neither TDP-43 mutant showed an
increased expression level (Fig. 3). Mutant TDP-43 may  thus at least
be quantitatively recognized as TDP-43 protein, but neither TDP-43
mutant worked to adjust the total expression level. This response
was marked and the difference between normal TDP-43 and TDP-
43 mutants associated with the regulation of RNA metabolism and
protein expression. Alternatively, this response may  be in part
related to the lack of 3′UTR TDP-43 mutants. It has previously been
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hown that TDP-43 expression is auto-regulated by feedback mech-
nisms via its own 3′UTR (Ayala et al., 2011; Polymenidou et al.,
011; Avendan˜o-Vázquez et al., 2012). Our experiments show the
ifferences between two mutants occurred in the absence of 3′UTR,
ndicating that the expression state of TDP-43 is regulated not only
ia 3′UTR but also each amino acid substitution in the C-terminal
omain of TDP-43, e.g. depending on protein half-life the mutant
roteins. We  note that the TDP-43 mutant mouse model reported
ere was critical to this discovery.
We then hypothesized that the different expression patterns
f the two TDP-43 mutants occurred in peripheral blood (Fig. 4).
he protein levels in the A382T mutant were signiﬁcantly higher
han those in G348C, and this result is consistent with those
resented above (Fig. 5A). In addition, high non-uniformity of
ransgene expression was found in A382T mutant WBCs. Although
ore molecular biological investigations of this non-uniformity are
equired, the expression states of TDP-43 may  be similar between
NS and WBCs. In one previous study, mislocalization of TDP-
3 was observed in circulating lymphomonocytes of ALS patients,
hus conﬁrming our present results (De Marco et al., 2011). Taken
ogether, we believe that these CNS phenomena can be detected in
BCs and can be used as biomarkers in ALS diagnosis.
To assess the clinical meaning of our results, we  analyzed ﬂu-
rescent signals detected by TDP-43 antibody in WBCs in WT
ice. We  attempted neurodegenerative diagnosis by performing an
maging study of WBCs for the ﬁrst time. We  characterized TDP-43
xpression patterns by modifying the TV lens system of a micro-
cope and using imaging software (Figs. 4 and 5). In A382T mutant
ice at the presymptomatic stage, the total TDP-43 expression lev-
ls were higher than those in WT  and G348C mice (Fig. 5B). In
ddition, the cell localization of TDP-43 was highly dispersed in
382T only (Fig. 5C and D). Taken together, our results suggest that
hese phenomena are associated with an abnormality in TDP-43
etabolism in WBCs. In addition, these abnormal states of TDP-43
ay  differ between mutational positions, which may  have caused
onfusions in the development of biomarkers of ALS diagnosis in
he past.
In recent investigations, abnormal RNA metabolism was  found
o be associated with neurodegeneration (Linder et al., 2015). Fur-
hermore, several previous reports have shown RNA metabolism in
eripheral blood. For example, microarray analysis was performed
sing peripheral blood mononuclear cells of ALS patients, and a
umber of biomarker candidates were proposed (Mougeot et al.,
011). Additionally, some have focused on microRNA accumula-
ions. For instance, miR-1234-3p and miR-1825 have been found to
e downregulated in the serum of ALS patients (Freischmidt et al.,
015). To detect abnormalities in whole blood cells, we investigated
RNA expression of biomarker candidates using WBCs of KI mice.
imilar to what was observed on imaging of WBCs (Fig. 5), mRNA
xpression of A382T was higher than G348C in WBCs (Fig. 6B).
hanges in the metabolism of TDP-43 in the CNS may  thus also
e observed in WBCs.
We focused on MN  degenerative factors that have been reported
o regulate MN  survival and anti-apoptosis. We examined mRNA
etabolism of the two mutant human TDP-43 in WBCs of KI mice.
MN protein was found to be ubiquitously expressed in various
issues, including WBCs, but its level was particularly high in MNs
Pellizzoni et al., 1998). The protein functions in the cytoplasmic
ssembly of snRNP particles that form spliceosomes (Pellizzoni
t al., 1998). As shown in a recent study, SMN  protein is co-regulated
ith TDP-43 (Tsuiji et al., 2013). Reﬂecting this, SMN  mRNA levels
ere consistent with those of total TDP-43 in the WBCs of our KI
ice (Fig. 6A and C). Smn1 was not included as a candidate in the
DP-43 KD transcription assay, whereas mRNA of Smn1 decreased
n the FUS/TLS KD transcription assay (Lagier-Tourenne et al., 2012).
t has been reported that the transcription of Smn1 is regulatedResearch 106 (2016) 12–22
by FUS/TLS. These ﬁndings suggest that Smn1 expression may be
related to the pathology of ALS caused by TDP-43 and FUS/TLS.
Notably, we demonstrated that ﬂuctuations in Smn1 expression
arise in WBC  of ALS model mice. Another interesting factor is NAIP,
a member of the Inhibitor of Apoptosis Protein gene family. The
protein has also been shown to be ubiquitously expressed with
high levels in the CNS, and functions as an apoptosis suppressor
that blocks the activities of caspase-3 and caspase-7 (Robertson
et al., 2000). NAIP has previously been reported to suppress MN
death in an ALS mouse model (mutant SOD1 expressing transgenic
mice) (Tanaka et al., 2014). In our KI mice, NAIP mRNA levels were
opposite to that of SMN  and total TDP-43 (Figs. 6A, C and D). Naip5
was not a candidate of RIP-seq of FUS/TLS, while mRNA of Naip2
has been reported to function as a binding molecule to FUS/TLS
(Colombrita et al., 2012). It is thought, including our result, both of
Naip2 and Naip5 which were included in the Lgn1 locus related to
immunoreaction (Diez et al., 2003) could be useful biomarkers of
ALS pathology. Naip5 may  be an especially useful biomarker in ALS
model mice, given its high levels of expression in WBC  compared to
other Naip family members. These results suggest that Smn1 and
human Naip may  also serve as useful biomarkers of human ALS.
Our ﬁndings may  imply that two factors are associated with the
MN degenerative response to changes in total TDP-43 expression.
Moreover, responses were different between A382T and G348C
mutant TDP-43 KI mice, which may  have been caused by mutant
TDP-43 expression level. To investigate regulation of TDP-43, a
splice variant of NAIP was examined at the transcriptional level
(Fig. 6E). Although we  failed to detect changes using the ratio of
splice variants to NAIP, it is possible that an unknown factor causes
the accumulation of abnormal splice variants, leading to aberrant
RNA metabolism following neurodegeneration. In addition, the two
MN degeneration-related factors are known to play crucial roles in
spinal muscular atrophy (SMA) pathology (Lefebvre et al., 1995;
Roy et al., 1995). It has been proposed that the mechanisms under-
lying ALS and SMA  are linked (Tsuiji et al., 2013). Consequently, it
is possible that the metabolism of SMN  and NAIP could be used to
detect MN degeneration.
Taking a molecular cell biology perspective, we next focused
on apoptosis mechanisms, which have been reported to be associ-
ated with TDP-43, SMN, and NAIP. Although apoptosis is induced
by several stimuli, most activated apoptosis signals are ultimately
consolidated in the same pathway and thus these factors may
be involved in part of the pathway. TDP-43 is known to regulate
expression of Bcl-2 protein, which is a well-known cell death-
modulating factor (Sephton et al., 2011). Caspase-9, an apoptosis
inducer, is activated by Bcl-2 and leads to the activation of caspase-
3, which is known to be an apoptosis effector (Ulukaya et al., 2011).
The SMN  protein also interacts with Bcl-2 and enhances apoptotic
activity (Iwahashi et al., 1997). We  performed an exon array anal-
ysis in WBCs of KI mice and found that the mRNA level of NAIP
differed between WT  and A382T mutant mice (Fig. S6). Although
the binding mechanism is unclear, NAIP may  be regulated by TDP-
43 and enhance dysfunction of the apoptotic pathway. In a previous
report, mutant TDP-43 (M337V) was found to enhance the levels
of cleaved caspase-3 (Mutihac et al., 2015). This suggests that the
dysfunction of intracellular signaling associated with mutant TDP-
43 may  occur at various stages of apoptosis. We  have detected the
molecular biological symptoms of cell death in WBCs.
We show that the MN  death pathway is related to the function
of RNA regulation and may  be detectable in WBCs. At present,
the function of TDP-43 in RNA regulation is being investigated by
many groups. For example, non-sense-mediated decay has been
shown to occur after deleting a part of the non-coding exon of
TDP-43 (Polymenidou et al., 2011). Furthermore, aberration of the
TDP-43 splice variant has been reported in the spinal cords of ALS
patients (Xiao et al., 2015). Taken together, these results suggest
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hat TDP-43-related abnormal RNA metabolism could be used as a
arker of neurodegeneration.
In conclusion, we ﬁnd that a combination of TDP-43 and an
N  degeneration factors can be used to reﬂect abnormal RNA
etabolism in WBCs and thus be useful as ALS-onset biomark-
rs. Our results strongly suggest that a combination of candidate
iomarkers can detect aberrations in RNA levels in ALS patients.
his approach may  be useful in neurodegenerative biomarker
evelopment.
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